Suneva Medical Completes Initial Treatment in Phase 3 Acne Scar Study

Suneva Medical, Inc. announced that it has completed the enrollment and initial treatment of patients in its Phase 3 acne scar study. This multi-center, prospective study is investigating the efficacy of Artefill for the treatment of moderate to severe atrophic acne scars. Artefill is a dermal filler approved by the FDA in 2006 for the correction of the nasolabial folds commonly known as “smile lines.” This announcement follows several significant corporate developments for Suneva Medical in recent months. As previously announced, the company acquired Refissa and its generic equivalent, the only tretinoin cream currently available with a .05% strength, emollient base and broad indication for fine facial lines, hyperpigmentation, and tactile roughness. Suneva Medical also previously announced the official roll-out of ReGenica™ Skincare, a next-generation, growth factor skincare line.